Compare Amgen, Inc. (AMGN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. The key difference: Amgen, Inc. pays a 2.42% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VCIT | |
|---|---|---|
Market Cap | $225.71B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $84.82 |
52-Week Low | $271.18 | $81.07 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.42, up 0.17% over 24 hours. The technical outlook is neutral with bearish moving averages, while recent news highlights its low 0.03% expense ratio and competitive yield. Dividend distributions are scheduled through mid-2026, providing steady income.
The ETF offers a balance of yield and moderate risk through investment-grade corporate bonds. Key risks include interest rate sensitivity and economic volatility. Analyst sentiment is mixed, emphasizing cost efficiency but cautioning on duration exposure in a shifting rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
